The clinical impact of major comorbidities on idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating disease with a median survival time of 2-3 years after diagnosis. Patients with IPF exhibit distinct patterns of disease progression, and some patients display a more rapidly progressive clinical course. The clinical course of IPF may also include periods of acute deterioration, which are termed acute exacerbations. Patients with IPF frequently experience various comorbidities, such as pulmonary infection, emphysema, pulmonary hypertension, lung cancer, gastroesophageal reflux, cardiovascular disease, diabetes mellitus, and obstructive sleep apnea. A previous age- and sex-matched study showed that IPF itself was an independent risk factor for these comorbidities. Other studies have demonstrated that these comorbidities are associated with disease progression and mortality in IPF. These variations in the clinical course and comorbidities have affected the researchers' and physicians' understanding of IPF. Therefore, better identification and understanding of these variations may be helpful when making decisions regarding therapeutic interventions. Furthermore, the identification and treatment of comorbidities may have a clinically significant impact on patient survival. Future studies should use well-established definitions for distinct progression patterns and comorbid conditions to obtain greater insights into the pathogenesis and treatment of IPF.